Atara Biotherapeutics, Inc.
ATRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $129 | $9 | $64 | $20 |
| % Growth | 1,404% | -86.5% | 212.6% | – |
| Cost of Goods Sold | $21 | $9 | $0 | $282 |
| Gross Profit | $108 | -$0 | $64 | -$262 |
| % Margin | 83.7% | -3.7% | 100% | -1,286.4% |
| R&D Expenses | $151 | $225 | $273 | $282 |
| G&A Expenses | $40 | $51 | $72 | $79 |
| SG&A Expenses | $40 | $51 | $72 | $79 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$282 |
| Operating Expenses | $191 | $276 | $344 | $79 |
| Operating Income | -$83 | -$276 | -$281 | -$340 |
| % Margin | -64.7% | -3,219.5% | -441.2% | -1,673.9% |
| Other Income/Exp. Net | -$2 | -$0 | $52 | $0 |
| Pre-Tax Income | -$85 | -$276 | -$228 | -$340 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$85 | -$276 | -$228 | -$340 |
| % Margin | -66.2% | -3,220.9% | -359.1% | -1,672.3% |
| EPS | -11.41 | -65.18 | -55.96 | -90.78 |
| % Growth | 82.5% | -16.5% | 38.4% | – |
| EPS Diluted | -11.41 | -65.18 | -55.96 | -90.78 |
| Weighted Avg Shares Out | 7 | 4 | 4 | 4 |
| Weighted Avg Shares Out Dil | 7 | 4 | 4 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $5 | $3 | $0 |
| Interest Expense | $5 | $5 | $0 | $0 |
| Depreciation & Amortization | $5 | $5 | $6 | $9 |
| EBITDA | -$76 | -$266 | -$222 | -$331 |
| % Margin | -58.7% | -3,102.7% | -349.6% | -1,627.9% |